• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

    KemPharm Receives $10M Milestone for FDA Approval of Azstarys

    Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

    Syneos, Medable Partner for New Decentralized Capabilities

    CSafe Global Appoints SVP of Technology and Innovation
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Evotec to Build Second Biologics Mfg. Facility in Toulouse

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    TraceLink Introduces Opus Platform

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines

    KemPharm Receives $10M Milestone for FDA Approval of Azstarys

    Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax

    Syneos, Medable Partner for New Decentralized Capabilities

    Valneva’s Inactivated, Adjuvanted COVID-19 Vax Achieves Positive Data
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Unifying Quality Manufacturing to Drive Speed, Collaboration, and Compliance

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    PCI Pharma Services

    Almac Group

    Adare Pharma Solutions

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Baxter BioPharma Solutions

    Reed-Lane

    Emergent BioSolutions

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Biopharma Over 20 Years

    A look at the key trends that have impacted the biopharma industry over the years.

    Biopharma Over 20 Years
    Biopharma Over 20 Years
    Figure 1. Selected responses—SINGLE most important biomanufacturing trend, 2014-2019.1
    Biopharma Over 20 Years
    Figure 2. Selected data—estimated average % of activity outsourced 2019.1
    Biopharma Over 20 Years
    Figure 3. Selected regions considered a likelihood for CMO outsourcing within 5 years.1
    Biopharma Over 20 Years
    Figure 4. Planned future capacity expansion, Biotherapeutic Developers vs CMOs.1
    Related CONTENT
    • Oakwood Labs
    • Taros Chemicals
    • Sekisui
    • A Pharmaceutical Smörgåsbord
    • Vineti, WuXi AppTec Ink Personalized Therapy Management Platform Pact
    K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates11.20.19
    BioPlan Associates has followed the bioprocessing industry for 30 years, since 1989, and we have taken note and reported on advances and critical issues in this field through our 16th Annual Report of Biopharmaceutical Manufacturing Capacity and Production.1 This annual study provides insights from over 220 global bioprocessing professionals. In this article we point out just a few of the significant trends, changes and developments affecting the industry over the past decades as they affect contract manufacturing and outsourcing. Some of the most noteworthy include:

    • Changes and new developments in manufacturing efficiency and productivity;
    • The rapid expansion of outsourcing as a viable option for the industry;
    • The proliferation of new companies and bioprocessing technologies; and
    • The upward trend of FDA approvals for new biopharmaceutical products.

    Changes and New Developments in Manufacturing Efficiency and Productivity
    Overall improvement in manufacturing efficiency (Figure 1) has allowed the industry to avoid the production bottleneck that was of concern several years ago. An important aspect of the overall trend in increasing efficiency and productivity has been the improvement over the years in expression systems, which has allowed companies to generate more grams of protein per liter without having to increase the size and numbers of their bioprocessors. This was accomplished, in part, by many small yet incremental improvements in cell line performance. Over the years, companies and academics have looked at numerous options to achieve this goal.


    Figure 1. Selected responses—SINGLE most important biomanufacturing trend, 2014-2019.1

    While there is continuing interest in expanding the menu of mammalian expression systems, for the most part, new candidates have failed to measure up to the venerable Chinese Hamster Ovary (CHO) workhorse, which has come to dominate the industry. But not only is the CHO system the prevailing player among mammalian options, but the industry appears to have little interest in expanding the role of microbial bioprocessing options, which has not increased significantly in the last 20 years. There are many reasons for the decision to concentrate efforts on the CHO expression system, including higher fidelity of transcription and more authentic glycosylation. But paramount is the fact that success breeds success: as more knowledge of the properties and limitations of CHO piles up, investigators have not ventured into uncharted waters. Moreover, there are a wide variety of different strains of CHO available as open resources, without patent restrictions, which have been modified for a wide range of purposes.

    A robust CHO system, responding easily to further engineering, and endowed with multiple selective markers is a tempting plum, especially with the ongoing move to single platform manufacturing at commercial scale. Thus the industry is continuing a trend toward the use of a single platform for expression of a wide range of products.

    Other areas for innovation improvements in upstream manufacturing have greatly increased titers in recent years. Much of this is due not only to improved cell lines, expression systems and genetic engineering, but also to improved culture media and optimized additives. With augmentations in these and other areas, users have now been expressing desires for comparable upgrades in automation and in bags, connectors, and other equipment. Downstream purification processes, on the other hand, remain little changed and are increasingly a major limiting factor in commercial-scale biopharmaceutical manufacture.

    Another area of expansion over the years has been the adoption of single use components in manufacturing. Earlier, single use technology expanded rapidly but may have now reached a saturation point. As noted, the increases are dramatic, in some cases a doubling in the last five years. The single use technologies have greatly increased overall efficiency of the manufacturing process, as they allow manufacturers to avoid laborious cleaning and quality control of reusable and stainless steel devices. For example, in upstream clinical production, on average, 47.5% of facility unit operations substantially involved single-use devices.

    Rapid Expansion of Outsourcing as a Viable Option
    Outsourcing is becoming an increasingly important component of bioprocessing company strategy. For example, as new technologies are introduced, it can be more cost effective to outsource certain aspects of the process rather than acquire the training and hardware to carry out many of these tasks in house. Figure 2 presents data on a variety of services that are increasingly outsourced; for example analytical testing is now outsourced by a third of the companies surveyed. Other activities such as toxicity testing and fill/finish operations are at the top of the list.


    Figure 2. Selected data—estimated average % of activity outsourced, 2019.1

    Analytical testing is a leading outsourcing activity in all regions. But as we evaluate these trends regionally, we find that in general, there appears be a trend for U.S. and Western European biomanufacturers to concentrate more on optimization and incremental bioprocessing improvements, while Rest-of-World bioprocessors are more concerned with basic aspects and operations, and availability of support services, such as analytical testing and validation services. This is to be expected. ROW biomanufacturers appear to generally be devoting more effort and are seeing the most improvements in the more basic aspects of process control and development, while U.S. and Western European companies with more mature bioprocessing tend to report improvements in more specific areas and involving optimization rather than the most basic aspects of bioprocessing.

    The countries playing a major role in outsourcing are also notable (Figure 3). While the USA remains the predominant preference, China is now viewed favorably by an increasing percentage of respondents, with Germany, a traditional supplier in third place. China’s rise as a potential outsourcing destination is surprising given the fact that just seven years ago, China was essentially not included as part of the industry’s consideration set.


    Figure 3. Selected regions considered a likelihood for CMO outsourcing within 5 years.1

    The rise of contract manufacturing organizations (CMOs) has proven to be another defining feature of the bioprocessing industry in recent decades. Outsourcing is increasingly viewed as a desirable option, in part due to the increasing complexity of the technology that may require highly trained staff and specialized instrumentation. Thus, in the future not only will routine services and products with smaller markets be outsourced more frequently, but also more specialized technologies such as cellular and gene therapies.

    The Proliferation of New Companies and Bioprocessing Technologies
    The biopharmaceutical sector of the international economy continues its robust growth, and CMOs track the overall sector at 12% annual growth. This figure is one many staid, reliable industries can only dream of. Total annual biopharmaceutical revenue was $3.4 billion in 2018 and is expected to grow to approximately $3.8 billion in the current year.

    And projections of planned future capacity expansion in the next five years paint a rosy picture. Mammalian cell culture, microbial fermentation, and cell and gene therapy are all slated for large scale expansions in the coming years (Figure 4). This expansion drives both the biopharma companies and the CMOs, which are the beneficiaries of the push toward increased outsourcing.


    Figure 4. Planned future capacity expansion, Biotherapeutic Developers vs CMOs.1

    CMOs play an outsized role in the industry. Currently CMOs produce approximately 30% of recombinant commercial products, with a handful of large companies dominating the sector. These companies provide R&D expertise and early phase support, so the predominant picture today is of the CMOs playing an even larger role in the early aspects of product development than with commercial manufacturing. As bioprocessing technology matures, it gains in sophistication and complexity, so we can anticipate that CMOs will become increasingly advanced in their mastery of highly demanding and complex protocols. Because CMOs have been involved in a wider range of projects, they are likely to have command of a greater range of technologies.

    Historically, the well-established pharma giants employed outsourcing as a way of controlling staff and resources. Today they tend toward more compelling decision making, taking into account their core competencies and balancing their internal strengths with the benefits of specific outsourcing needs. In this approach, they scan the nooks and crannies of their operation, so every aspect is evaluated as a viable outsourcing candidate.

    With the growing number of biopharmaceuticals in the developmental pipeline, there is substantial effort within CMOs to hone their skills in order to deal with a wide range of molecules, not limited to recombinant proteins and monoclonal antibodies, but also encompassing a plethora of novel products such as highly engineered antibodies with modified cores and backbones, antibody conjugates, cellular and gene therapies and many other unusual and innovative classes of molecules and their derivatives. Any of these new strategies are moving ahead rapidly.

    Large scale, commercial development of various biologics will require the use of single-use bioreactors and expansion of new facilities. BioPlan has documented2 around 180,000 L of single use systems with capabilities in excess of 1000 L. There is a probability that the rapid expansion of single systems will take place at the expense of stainless steel-based bioprocessing.

    Although the U.S. was for a long time the dominant player in the industry, recent years have seen competitors from all over the world popping up, especially in China and Latin America. Chinese companies in particular have reached out aggressively, with WuXi investing $60 million to build a manufacturing facility in Worcester MA, in addition to plans to construct a $392 million biologics manufacturing facility in Dundalk, Ireland.

    Another important trend over the decades has been the increase in average commercial scale titers, from an estimated 1.1g/L as far back as 2003 to a current level of 3 g/L or more. At the same time, the number of FDA approved recombinant therapeutics has increased dramatically, with a record of 31 approvals in 2017.

    A description of trends in the bioprocessing industry would be incomplete without mentioning the concern in the early part of this century over a capacity crunch, which was envisioned as an inability of the commercial manufacturing industry to meet the demands of numerous new products coming online. This crunch did not occur for a variety of reasons which were unforeseen at the time by industry analysts. Most significantly, innovation in media, cell lines and equipment, especially the rise of disposables made it possible to increase capacity whiling taking on multiple projects at the same time.

    Gene therapy is another important trend within the industry, requiring different areas of expertise. The production of gene therapy reagents is complex and demanding, so CMOs will need to cultivate highly trained staff to produce these potential treatment options. For this reason these companies are in the midst of expanding their capacity and expertise.

    The 16th Annual Report recently summarized ongoing trends in the biopharmaceutical industry, summarizing the state of the industry as “dynamic and complex.” The report argues that the coming years will see the extension of current movements within the industry. Bioprocessing productivity will continue to increase, especially at the upstream end. Reports of expression rates of monoclonal antibodies at titers of  > 5 g/L in 14 day fed batch production are common. Such robust values enable the use of smaller scale (2000 L) bioreactors for commercial production, and allow smaller firms to be competitive in the CMO marketplace.

    Moreover, the proliferation of new biosimilar and biogeneric products entering the world marketplace, with hundreds in development or already in the biotechnology bazaar, combined with new follow-on biopharmaceuticals, opens a vast landscape for exploitation by newly expanding companies. These advances drive the expansion of the industry to meet the current facility constraints that are causing bottlenecks in production. These bottlenecks also factor into the demand among consumers for further innovation in the field of continuous bioprocessing.

    A natural outcome of a dynamic industry is the push to reduce manufacturing costs, which traditionally were not considered an important factor since the selling price of the drug was dictated by value added to patients overall quality of life. However, with the rapid expansion of the industry, companies are negotiating harder with CMOs to reduce product costs. 

    Overall, the 16th Annual Report posits that with strong overall growth we are seeing a substantial increase in facilities bioprocessing budgets, up an average of 8.2% in 2018, hardly surprising when one contemplates the ruddy health of the overall industry.

    Given current activities in the industry, it is to be anticipated that that American entrepreneurs would not be left alone in a world demanding their services. So, we see not only Asian companies, with 25% of the market, but also Western Europe with over 33%, mashing in on the U.S., always the major player, with 37% of capacity.

    Upward Trend of FDA Approvals for New Biopharmaceuticals
    It is noteworthy that approximately 25 new biopharmaceuticals were approved by the FDA in 2018, swelling an already large proliferation of already approved biologics. As patent protection expires on older products, they will morph into biosimilars, available for exploitation, again expanding the growing market.

    The changes taking place within the bioprocessing industry have enabled faster, more efficient and more economical development of new biotherapeutics. During the early period in the development of biologics, the process was laborious, and the rate of new approvals was modest. With the passage of time, both the industry and the regulatory sphere have streamlined their administrative arms, and evaluation of new drug entities move ahead much more rapidly than in the past. One of the most recent regulatory changes designed to accelerate the process was the regenerative medicine advanced therapies (RMAT) designation under the 21st Century Cures Act which is now part of the FDA program for moving new cell therapies through an accelerated approval process. 

    Conclusion
    Aside from being buffeted by many broader worldwide and pharmaceutical industry trends, the biopharmaceutical industry is continuously evolving and demanding new and improved bioprocessing technologies to reduce costs, increase efficiencies, and improve weak development pipelines. In fact, most large pharmaceutical companies are now spending 40-50% or more of their R&D on biopharmaceuticals.

    Along with and facilitating this trend, incremental innovation in improved manufacturing productivity continues unabated, driving many biopharmaceutical trends. This is exemplified by constant incremental increases in upstream titers. Innovation and expanded options also speed discovery, increase flexibility, and can drive down costs while improving productivity. The current situation in biopharma is exciting, with new technologies, biosimilars, cellular and gene therapies, and other major opportunities in both established and emerging markets. 

    References
    1. 16th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, April 2019, www.bioplanassociates.com/16th
    2. Langer, E., and Rader, R. The outlook for CMO outsourcing in 2019. Biopharma International 32(1):8-10.


    K.John Morrow,  PhD, is a long-time collaborator with BioPlan Associates, Inc. He is president since 2005 of Newport Biotechnology Consultants and has written many articles for Genetic Engineering and Biotechnology News, Life Science Leader, and other Biotechnology journals.

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports. elanger@bioplanassociates.com, +1 301-921-5979, www.bioplanassociates.com
    Related Searches
    • Outsourcing
    • biosimilars
    • bioprocessing
    • it
    Suggested For You
    Oakwood Labs Oakwood Labs
    Taros Chemicals Taros Chemicals
    Sekisui Sekisui
    A Pharmaceutical Smörgåsbord A Pharmaceutical Smörgåsbord
    Vineti, WuXi AppTec Ink Personalized Therapy Management Platform Pact Vineti, WuXi AppTec Ink Personalized Therapy Management Platform Pact
    Shortfalls in Advanced Therapy Production & Growth in China Bio Capacity Shortfalls in Advanced Therapy Production & Growth in China Bio Capacity
    Contract Pharma’s 20th Anniversary Series: CDMO Insight Contract Pharma’s 20th Anniversary Series: CDMO Insight
    Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future
    Vetio Animal Health Vetio Animal Health
    TrakCel, WuXi AppTec Enter Strategic Supply Chain Pact TrakCel, WuXi AppTec Enter Strategic Supply Chain Pact
    Contracting And Outsourcing Agenda Contracting And Outsourcing Agenda
    Quality Metrics Feedback Quality Metrics Feedback
    It’s Showtime! It’s Showtime!
    FDA Extends CRADA with CluePoints FDA Extends CRADA with CluePoints
    NIIMBL, FDA to Advance Innovation in Bio Manufacturing NIIMBL, FDA to Advance Innovation in Bio Manufacturing

    Related Features

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20

    • Biosimilars
      Biosimilar Manufacturing Strategies

      Biosimilar Manufacturing Strategies

      Five steps to competing in a post-patent expiry era.
      George I’ons, Owen Mumford Pharmaceutical Services 09.09.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20


    • Biologics, Proteins, Vaccines
      CAR-T Cell Therapy in Clinical Trials

      CAR-T Cell Therapy in Clinical Trials

      The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus
      Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD 06.04.20

    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20

    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20


    • Biosimilars
      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      Biosimilar uptake set to reshape the U.S. market
      Katya Svoboda and Bob Swann, ICON 05.05.20

    • Biologics, Proteins, Vaccines
      CEO Spotlight: Dr. Tae Han Kim

      CEO Spotlight: Dr. Tae Han Kim

      Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic
      Tim Wright, Editor, Contract Pharma 05.05.20

    • Biologics, Proteins, Vaccines
      Covid 19: Impact on Bioprocessing and Outsourcing

      Covid 19: Impact on Bioprocessing and Outsourcing

      Outsourcing of biologics is increasing due to Covid-19, but what will change in the long-run?
      Ronald A. Rader & Eric S. Langer, BioPlan Associates 05.05.20


    • Biologics, Proteins, Vaccines
      The Evolution of the ADC Manufacturer

      The Evolution of the ADC Manufacturer

      How CMDOs can rise to the occasion
      Lisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20

    • Biologics, Proteins, Vaccines
      Biopharma Contract Manufacturing Pricing Analysis

      Biopharma Contract Manufacturing Pricing Analysis

      Expect increased prices over the next two years, but at slightly lower than historical trends
      William Downey, HighTech Business Decisions 01.28.20

    • Biologics, Proteins, Vaccines | Parenterals
      A Changing Healthcare Landscape

      A Changing Healthcare Landscape

      Navigating the road ahead with a focus towards patient centricity
      Peter Soelkner, Vetter Pharma International GmbH 01.28.20

    Trending
    • Franco Negron Named CEO Of ApiJect Systems America
    • Obituary Notice: Russell “Russ” Haines
    • Resilience Acquires Ology Bioservices
    • Johnson & Johnson 1Q Results
    • RDIF, Hualan Ink COVID-19 Vaccine Deal
    Breaking News
    • Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    • KemPharm Receives $10M Milestone for FDA Approval of Azstarys
    • Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax
    • Syneos, Medable Partner for New Decentralized Capabilities
    • CSafe Global Appoints SVP of Technology and Innovation
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Ashland Supports the Nature Conservancy Forest Restoration Effort to Help Plant a Billion Trees
    Martin Bauer Announces Installation of Agile Filling System at Bethlehem, PA Facility
    PepsiCo and Ingredion Begin Pilot Partnership with Soil and Water Outcomes Fund
    Coatings World

    Latest Breaking News From Coatings World

    AkzoNobel Shareholders Approve Final Dividend at Annual General Meeting
    PPG Maintains EcoVadis Gold Rating
    Sustainable Plastics Will Make Up More Than 15% of Production by 2030
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Getinge Receives FDA Clearance for Multiple Products
    Study Shows Benefits of CCHD Screening Using Masimo SET Pulse Oximetry
    TEAM Technologies Acquires ViruDefense
    Contract Pharma

    Latest Breaking News From Contract Pharma

    RDIF, Minapharm to Make Over 40M Doses of the Sputnik V Vaccine in Egypt
    Bora Pharmaceuticals Completes Health Canada Inspection
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Knoll Printing & Packaging Commits to a Healthy Ocean and Planet
    New Sustainable Jar from APC Packaging
    Qosmedix Launches Corporate Social Responsibility Initiative
    Happi

    Latest Breaking News From Happi

    Multi-Purpose Sustainable 'Just Add Water' Household Cleaner Expands Cleaning Products
    Kao Launches Oribe in Japan
    Love Beauty and Planet Shares Sustainability Initiatives With Refillable Hair Care at Target
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    SE-DA Invests in Kornit Presto S
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Epson upgrades SurePress demo facility
    Xeikon helps converters navigate toner and inkjet
    Mactac introduces Simply Sustainable initiative
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Savaré Strengthens Technical Support for the Americas
    FiberVisions, Avgol Partner with Polymateria
    High-Tech Conversions Launches Wipes Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Clears Orthofix's 3D-Printed FORZA Titanium TLIF Spacer System
    Patients Conclude Clinical Visits in Knee Osteoarthritis Treatment Study
    SeaSpine Begins Limited Rollout of WaveForm TO 3D-Printed Interbodies
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Identiv, Ameta International Announce US, Canadian Distribution Partnership
    Adesis Achieves ISO 9001:2015 Certification
    Louis Widmer SA Complies with EU Anti-Counterfeiting Directive with Zebra Technologies’ Solution

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login